Editing Clozapine (section)

===Weight gain and diabetes===
In addition to [[hyperglycemia]], significant [[weight gain]] is frequently experienced by patients treated with clozapine.<ref>{{cite journal | vauthors = Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR | title = Novel antipsychotics: comparison of weight gain liabilities | journal = The Journal of Clinical Psychiatry | volume = 60 | issue = 6 | pages = 358–363 | date = June 1999 | pmid = 10401912 | doi = 10.4088/JCP.v60n0602 }}</ref> Impaired glucose metabolism and [[obesity]] have been shown to be constituents of the [[metabolic syndrome]] and may increase the risk of [[cardiovascular disease]]. The data suggest that clozapine may be more likely to cause adverse metabolic effects than some of the other [[atypical antipsychotics]].<ref name="pmid17848919">{{cite journal | vauthors = Nasrallah HA | title = Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles | journal = Molecular Psychiatry | volume = 13 | issue = 1 | pages = 27–35 | date = January 2008 | pmid = 17848919 | doi = 10.1038/sj.mp.4002066 | s2cid = 205678886 }}</ref> For people who gain weight because of clozapine, taking [[metformin]] may reportedly improve three of the five components of the metabolic syndrome: waist circumference, fasting glucose, and fasting triglycerides.<ref>{{cite journal | vauthors = Siskind DJ, Leung J, Russell AW, Wysoczanski D, Kisely S | title = Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis | journal = PLOS ONE | volume = 11 | issue = 6 | pages = e0156208 | date = 15 June 2016 | pmid = 27304831 | pmc = 4909277 | doi = 10.1371/journal.pone.0156208 | bibcode = 2016PLoSO..1156208S | veditors = Holscher C | doi-access = free }}</ref>